BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 3318323)

  • 1. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
    Akasaki M; Takashi T; Kita Y; Tsukada W
    Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of colony-stimulating factor from macrophages by muroctasin.
    Yamaguchi F; Akahane K; Takashi T; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):983-6. PubMed ID: 3263870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
    Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
    Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of immune responses by muroctasin.
    Akasaki M
    Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
    Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
    Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adjuvant effect of a muramyl dipeptide (MDP) analog on temperature-sensitive Salmonella mutant vaccine.
    Onozuka K; Shinomiya H; Cho N; Saito-Taki T; Nakano M
    Int J Immunopharmacol; 1989; 11(7):781-7. PubMed ID: 2689364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of plasma fibronectin production in mice by muroctasin.
    Endo N; Okuda T; Osada Y; Zen-Yoji H
    Arzneimittelforschung; 1988 Jul; 38(7A):997-8. PubMed ID: 3190806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
    Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
    Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
    Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
    Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo effects of MDP-Lys(L18) on mouse megakaryocyte progenitor cells (CFU-Meg).
    Komiya I; Kuriya S; Akahane K; Nomura T
    Exp Hematol; 1992 May; 20(4):517-22. PubMed ID: 1568468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid.
    Sugawara T; Takada S; Miyamoto M; Nomura M; Kato M
    Inflammation; 1996 Feb; 20(1):43-56. PubMed ID: 8926048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin.
    Yamaguchi F; Akasaki M; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):980-3. PubMed ID: 3263869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
    Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
    Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
    Nagao S; Sato K; Osada Y
    Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific binding sites of muroctasin on murine macrophages.
    Akasaki M; Masayasu H; Tsukada W; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.